title: Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature.
abstract: Vemurafenib has proved to be useful in the treatment of patients with unresectable or metastatic melanoma harboring the BRAF-V600E mutation, with better rates of overall and progression-free survival than previous treatments. Adverse cutaneous effects, such as alopecia, pruritus, photosensitivity reactions, verrucous keratosis, keratoacanthomas, or squamous cell carcinomas, have been described. Thirty cases of vemurafenib-associated panniculitis are available in the literature with variable clinical relevance. Only 9 of them exhibited definitive evidence of neutrophilic panniculitis. They all consist of multiple lesions, usually located in the lower limbs. Histopathologically, they have been described as predominantly neutrophilic, lymphocytic, or mixed, more commonly with lobular location. We report an additional case of neutrophilic panniculitis in a 45-year-old woman treated with vemurafenib for metastatic melanoma, presenting as a single lesion on his right leg. The lesion resolved spontaneously and did not need treatment reduction. The presentation of this condition with a single lesion is particularly challenging. Recognition of this association is important given the increasing use of vemurafenib and the potential implications of treatment withdrawal.
authors.affiliation: Departments of *Dermatology, and †Pathology, Clinical University Hospital and School of Medicine, Santiago de Compostela, Spain.
authors.forename: Igor
authors.initials: I
authors.lastname: Vázquez-Osorio
authors.forename: María Dolores
authors.initials: MD
authors.lastname: Sánchez-Aguilar
authors.forename: Sara
authors.initials: S
authors.lastname: García-Rodiño
authors.forename: José M
authors.initials: JM
authors.lastname: Suárez-Peñaranda
authors.forename: Carlos
authors.initials: C
authors.lastname: Aliste
authors.forename: Hugo
authors.initials: H
authors.lastname: Vázquez-Veiga
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D035002:Lower Extremity; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D020556:Neutrophil Infiltration / Q000187:drug effects*; D009504:Neutrophils / Q000187:drug effects* / Q000473:pathology; D015434:Panniculitis / Q000139:chemically induced* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib